

DAFTAR PUSTAKA

- Al Koudsi, N., Ahluwalia, J.S., Lin, S.K., Sellers, E.M., Tyndale, R.F., 2009. A novel *CYP2A6* allele (*CYP2A6*35*) resulting in an amino-acid substitution (*Asn438Tyr*) is associated with lower *CYP2A6* activity in vivo. *Pharmacogenomics J.* 9: 274–282.
- Al Koudsi, N., and Tyndale, R.F., 2010. Hepatic *CYP2B6* is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. *Xenobiotica.* 40: 381–392.
- Ariyoshi, N., Ohara, M., Kaneko, M., Afuso, S., Kumamoto, T., Nakamura, H., Ishii, I., Ishikawa, T., Kitada, M., 2011. *Q172H* replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by *CYP2B6* variant with *Arg262*. *Drug Metab Dispos.* 39: 2045–2048.
- Arnaldo, P., Ricardo, E.T., Marcia, Q.L., Philip, N.S., Adalberto, R.S., 2012. Frequencies of cytochrome *P4502B6* and *2C8* allelic variants in the mozambican population. *Malays J Med Sci.* 20 (4): 13-23.
- Barber S., Adioetomo S.M., Ahsan A., Setyonaluri D., 2008. Tobacco economics in Indonesia. Paris: International Union Against Tuberculosis and Lung Disease. [serial online] [cited 27 October, 2014]. Available from: URL:<http://www.tobaccofreeunion.org/assets/Technical%20Resources/Economic%20Reports/Tobacco%20Economics%20in%20Indonesia%20E%20N.pdf>.
- Benowitz, N.L., Hukkanen, J., and Jacob III, P., 2009. *Handbook of Experimental Pharmacology*. Springer-Verlag Berlin Heidelberg, San Fransisco.
- Binnington, M.J., Zhu, A.Z.X., Renner, C.C., Lanier, A.P., Hatsukami, D.K., Benowitz, N.L., and Tyndale, R.F., 2012. *CYP2A6* and *CYP2B6* genetic variation and its association with nicotine metabolim in South Western Alaska Native people. *Pharmacogenet Genomics.* 22 (6): 429-440.
- Crespi, C.L., Penman, B.W., Gelboin, H.V. and Gonzalez, F.J., 1991. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome *P4502D6*. *Carcinogenesis.* 12: 1197-1201.
- Dahlan, M.S., 2013. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. Edisi 3. Salemba Medika, Jakarta.
- Djodjevic, N., Carrillo, J.N., Broek, M.P.J.V.D., Kishikawa, J., Roh, H.K., Bertilsson, L., and Aklillu, E., 2013. Comparisons of *CYP2A6* genotype and enzyme activity between Swedens and Koreans. *Drug Metab Pharmacokinet.* 28 (2): 93-97.
- Detels, R., Beaglehole, R., Lansang, M.A., Gulliford, M., 2011. *Oxford Textbook of Public Health*. Oxford University Press, New York.
- Ellison, C.A., Abou El-Ella, S.S., Tawfik, M., Lein, P.J., and Olson, J.R., 2012. Allele and genotype frequencies of *CYP2B6* and *CYP2C19* polymorphisms in Egyptian agricultural workers. *J Toxicol Environ Health A.* 75 (4): 232–241.

- Ezzati, M. and Lopez, A.D., 2003. Estimates of global mortality attributable to smoking in 2000. *Lancet*. 362: 847–852.
- Fujieda, M., Yamazaki, H., Saito, T., Kiyotani, K., Gyamfi, M., Sakurai, M., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., and Kamataki, T., 2004. Evaluation of *CYP2A6* genetic polymorphisms as determinant of smoking behavior and tobacco-related lung cancer risk in male Japanese smoker. *Carcinogenesis*. 25 (12): 2451-2458.
- Fukami, T., Nakajima, M., Sakai, H., McLeod, H.L., and Yokoi, T., 2006. *CYP2A7* polymorphic alleles confound the genotyping of *CYP2A6*4A* allele. *The Pharmacogenomics journal*. 6: 401-412.
- Fukami, T., Nakajima, M., Yamanaka, H., Fukushima, Y., McLeod, H.L., Yokoi, T., 2007. A novel duplication type of *CYP2A6* gene in African-American population. *Drug Metab Dispos*. 35: 515–520.
- Gambier, N., Batt, A-M., Marie, B., Pfister, M., Siest, G., Visvikis-Siest, S., 2005. Association of *CYP2A6*1B* genetic variant with the amount of smoking in French adults from the Stanislas cohort. *The Pharmacogenomics journal*. 5: 271-275.
- Guan, S., Huang, M., Li, X., Chen, X., Chan, E., and Zhou, S.F., 2006. Intra- and inter-ethnic differences in the allele frequencies of cytochrome *P450 2B6* gene in Chinese. *Pharmaceutical Research*. 23 (9).
- Ho, M.K., Mwenifumbo, J.C., Al Koudsi, N., Okuyemi, K.S., Ahluwalia, J.S., Benowitz, N.L., 2009. Association of nicotine metabolite ratio and *CYP2A6* genotype with smoking cessation treatment in African-American light smokers. *Clin Pharmacol Ther*. 85: 635–643.
- Hukkanen, J., Peyton, J.III, and Neal, L.B., 2005. Metabolism and disposition kinetics of nicotine. *Pharmacol Rev*. 57: 79-115.
- Inui, N., 2010. *CYP2A6* (cytochrome P450, family 2, subfamily A, polypeptide 6). *Atlas of Genetics and Cytogenetics in Oncology and Haematology*. Springer-Verlag Berlin Heidelberg, San Fransisco.
- Jacob, R.M., Johnstone, E.C., Neville, M.J., and Walton, R.T., 2004. Identification of *CYP2B6* sequence variants by use of multiplex PCR with allele-specific genotyping. *Clinical chemistry*. 50 (8): 1372-1377.
- Kementrian Kesehatan RI., 2013. *Riset Kesehatan Dasar*. Badan Penelitian dan Pengembangan Kesehatan, Jakarta.
- Kementrian Perindustrian dan Perdagangan RI., 2004. *Pedoman Cara Uji Kandungan Kadar Nikotin dan Tar Rokok*. Kemenrindag, Jakarta.
- Kusuma, D.A., Sudarminto, S.Y., dan Siti, N.W., 2010. Studi kadar nikotin dan tar sembilan merk rokok kretek filter yang beredar di wilayah kabupaten Nganjuk. *J. Tek. Pert*. 5 (3): 151-155.
- Kumasaka, N., Aoki, M., Okada, Y., Takahashi, A., Ozaki, K., Mushiroda, T., Hirota, T., Tamari, M., Tanaka, T., Nakamura, Y., Kamatani, N., Kubo, M., 2012. Haplotypes with copy number and single nucleotide polymorphisms in *CYP2A6* locus are associated with smoking quantity in a Japanese population. *PLoS ONE*. 7 (9): 44507.

- Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M.L., 2003. Hepatic *CYP2B6* expression: gender and ethnic differences and relationship to *CYP2B6* genotype and *CAR* (constitutive androstane receptor) expression. *J Pharmacol Exp Ther.* 307: 906–22.
- Lee, A.M., Jepson, C., Shield, P.G., Benowitz, N., Lerman, C., and Tyndale, R.F., 2007. *CYP2B6* genotype does not alter nicotine metabolism, plasma level, or abstinence with nicotine replacement therapy. *Cancer Epidemiol Biomarkers Prev.* 16 (6).
- Loukola, A., Hallfors, J., Korhonen, T., Kaprio, J., 2014. Genetics and smoking. *Curr Addict Rep.* 1: 75-82.
- MacKillop, J., Ezemenari, M.O., Michael, T.A., John, E.M., Valerie, S.K., 2010. The role of genetics in nicotine dependence: mapping the pathways from genome to syndrome. *Curr Cardio Risk Rep.* (4): 446-453.
- Malaiyandi, V., Lerman, C., Benowitz, N.L., Jepson, C., Patterson, F., Tyndale, R.F., 2006. Impact of *CYP2A6* genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. *Mol Psychiatry.* 11: 400–409.
- Miksys, S.R. and F., Tyndale, 2006. Nicotine induces brain CYP enzymes: relevance to Parkinson`s disease. *J Neural Transm.* (70): 177-180.
- Minematsu, N., Nakamura, H., Furuuchi, M., Nakajima, T., Takahashi, S., Tatena, H., and Ishizaka, A, 2006. Limitation of cigarette consumption by *CYP2A6**4, *7, and *9 polymorphisms. *Eur Respir J.* 27: 289-292.
- Muliaty, D., Yusuf, I., Setiabudy, R., Wanandi, S.I., 2010. *CYP2A6* gene polymorphisms impact to nicotine metabolism. *Med J Indones.* 19:46-51.
- Murray, R.K., Daryl, K.G., Victor, W.R., 2013. *Biokimia Harper.* Edisi 27. EGC, Jakarta.
- Mwenifumbo, J.C., Myers, M.G., Wall, T.L., Lin, S.K., Sellers, E.M., Tyndale, R.F., 2005. Ethnic variation in *CYP2A6**7, *CYP2A6**8 and *CYP2A6**10 as assessed with a novel haplotyping method. *Pharmacogenet Genomics.* 15: 189–92.
- Mwenifumbo, J.C., Lessov-Schlaggar, C.N., Zhou, Q., Krasnow, R.E., Swan, G.E., Benowitz, N.L., 2008. Identification of novel *CYP2A6**1B variants: the *CYP2A6**1B allele is associated with faster in vivo nicotine metabolism. *Clin Pharmacol Ther.* 83: 115–121.
- Mwenifumbo, J.C., and Tyndale, R.F., 2007. Genetic variability in *CYP2A6* and the pharmacokinetics of nicotine. *Pharmacogenomics.* 8: 1385–1402.
- Mwenifumbo, J.C., Zhou, Q., Benowitz, N.L., Sellers, E.M., Tyndale, R.F., 2010. New *CYP2A6* gene deletion and conversion variants in a population of Black African descent. *Pharmacogenomics.* 11: 189–198.
- Nakajima, M., Yoshida, R., Fukami, T., McLeod, H.L., Yokoi, T., 2004. Novel human *CYP2A6* alleles confound gene deletion analysis. *Federation of European Biochemical Societies (FEBS Letters).* 569: 75-81.
- Nakajima, M., Fukami, T., Yamanaka, H., Higashi, E., Sakai, H., Yoshida, R., 2006. Comprehensive evaluation of variability in nicotine metabolism and *CYP2A6* polymorphic alleles in four ethnic populations. *Clin Pharmacol Ther.* 80: 282–297.

- Ng, M., Michael, K.F., Thomas, D.F., Margaret R., Laura, D-L., Blake, T., Alexandra, W., Ella, S., Sarah, W., Alan, D.L., Christopher, J.L.M., Emmanuela, G., 2014. Smoking Prevalence and Cigarette Consumption in 187 Countries 1980-2012. *JAMA*. 311(2): 183-192.
- Patramurti, C., Sugiyanto, Nurrochmad, A., Martono, S., 2014. Polymorphism of cytochrome P450 2A6 (*CYP2A6*1* and *CYP2A6*4*) among Javanese Indonesian smoker and non smoker. *Indonesian J.Pharm.* 26(1): 11-19.
- Quaak, M., Schayck, C.P.V., Knaapen, A.M., Schooten, F.J.V., 2009. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory disease. *Eur Respir J*. 33: 468-480.
- Schoedel, K.A., Hoffmann, E.B., Rao, Y., Sellers, E.M., Tyndale, R.F., 2004. Ethnic variation in *CYP2A6* and association of genetically slow nicotine metabolism and smoking in adult Caucasians. *Pharmacogenetics*. 14: 615–626.
- Shuwen, H., Cook, Derek, G., Hinks, Lesley, J., Chen, Xio-He, Ye, Shu, Gilg, Julie, A., Jarvis, Martin, J., Whincup, Peter, H., Day, Ian, N.M., 2005. *CYP2A6*, *MAOA*, *DBH*, *DRD4*, and *5HT2A* genotypes, smoking behavior and cotinine level in 1518 UK adolescents. *Pharmacogenetics and Genomics*. 15(12): 839-850.
- Sreeramareddy, C.T., Pradhan, P.M.S., Mir, I.A., dan Sin, S, 2014. Smoking and smokeless tobacco use in nine South and Southeast Asian countries: prevalence estimates and social determinants from Demographic and Health Surveys. *Population Health Metrics*. 12: 22.
- Sudiantara, Y., 1998. *Nilai-nilai hidup dalam masyarakat Jawa* [tesis]. Universitas Katolik Soegijapranata, Semarang.
- Sundberg, M.I., Sim, S.C., Gomez, A., Antona, C.R., 2007. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoeigenetic and clinical aspect. *Pharmacology & Therapeutics*. 116: 496-526.
- Thorn, C.F., Lamba, J.K., Lamba, V., Klein, T.E., and Altman, R.B., 2010. PharmaGKB summary: very important pharmacogene information for *CYP2B6*. *Pharmacogenet Genomics*. 20(8): 520-523.
- Tyndale, R.F. and Sellers, E., 2005. Variable *CYP2A6*-mediated nicotine metabolism alters smoking behavior and risk. *The American Society for Pharmacology and Experimental Therapeutics*. 29 (4).
- Vasconcelos, G.M., Struchiner, C.J., Suarez-Kurtz, G., 2005. *CYP2A6* genetic polymorphisms and correlation with smoking status in Brazilians. *The Pharmacogenomics journal*. 5: 42–48.
- Wassenar, C.A., Qiong, D., Christopher, I.A., Margaret, R.S., and Rachel, F.T., 2013. Pilot study of *CYP2B6* genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis. *Int J. Mol. Sci.* (14): 8381-8392.
- World Health Organization, 2008. *Report on the global tobacco epidemic*. http://www.who.int/tobacco/mpower/mpower_report_full_2008.pdf.

- Yildiz, D., 2004. Nicotine, its metabolism and an overview of its biological effects (Review). *Toxicol.* 43: 619-632.
- Yoshida, R., Nakajima, M., Watanabe, Y., Kwon, J.T., Yokoi, T., 2002. Genetic polymorphisms in human *CYP2A6* gene causing impaired nicotine metabolism. *Br J Clin Pharmacol.* 54: 511–517.
- Zakeri, S., Amiri, N., Pirahmadi, S., Dinparast, Djadid, N., 2014. Genetic Variability of *CYP2B6* Polymorphisms in Southeast Iranian Population: Implications for Malaria and HIV/AIDS Treatment. *Arch Iran Med.* 17(10): 685 – 691.
- Zanger, U.M. and Kathrin, K., 2013. Pharmacogenetics of cytochrome P450 *2B6* (*CYP2B6*): advances on polymorphisms, mechanisms, and clinical relevance. *Frontiers in Genetics.* (4): 24.
- Zanger, U.M., and Klein, K., 2013. Pharmacogenetics of cytochrome *P450 2B6* (*CYP2B6*): advances on polymorphisms, mechanisms, and clinical relevance. *Frontiers in genetics.* 4 (24).
- Zanger, U.M., Klein, K., Saussele, T., Bliedernicht, J., Hofmann, M.H., Schwab, M., 2007. Polymorphic *CYP2B6*: molecular mechanisms and emerging clinical significance. *Pharmacogenomics.* 8: 743–759.
- Zanger, U.M., and Schwab, M., 2013. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics.* (138) : 103-141.